Litigation Details for Purdue Pharma L.P. v. Intellipharmaceutics International Inc. (D. Del. 2018)

Purdue Pharma L.P. v. Intellipharmaceutics International Inc. (D. Del. 2018)

Docket		Date Filed	2018-03-14
Court	District Court, D. Delaware	Date Terminated	2020-07-28
Cause	35:0145	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To	Sherry R. Fallon
Patents	8,309,060; 9,060,976; 9,073,933; 9,492,389; 9,492,391; 9,522,919; 9,675,610; 9,763,933; 9,775,808
Link to Docket	External link to docket

Details for Purdue Pharma L.P. v. Intellipharmaceutics International Inc. (D. Del. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-03-14				External link to document
2018-03-14	10		’808 patent”); 9,763,886 (the “’886 patent”); 9,763,933 (the “Mannion ’933 patent”); 8,309,060 (the “…RELIEF (PATENT INFRINGEMENT OF U.S. PATENT NO. 8,309,060) 123. … United States Patent Nos. 9,060,976 (the “’976 patent”); 9,073,933 (the “’933 patent”); 9,522,919 (the…(the “’919 patent”); 9,492,389 (the “’389 patent”); 9,492,391 (the “’391 patent”); 9,775,808 (the “’808… “’060 patent”); and 9,675,610 (the “’610 patent”) (collectively, “the patents-in-suit”). This action	External link to document
2018-03-14	122	Patent/Trademark Report to Commissioner of Patents	.763,886; 9.763,933; 9,675,610; 10,076,497 B2. (Attachments: # 1 Order)(nms) (Entered: 07/29/2020) … Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,775,808; 9.763,886…2018 28 July 2020 1:18-cv-00404 830 Patent None District Court, D. Delaware	External link to document
2018-03-14	5		,073,933; 9,522,919; 9,492,389; 9,492,391; 8,309,060; 9,775,808; 9,763,886; 9,763,933; 9,675,610. (sar… Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,060,976; 9,073,933…2018 28 July 2020 1:18-cv-00404 830 Patent None District Court, D. Delaware	External link to document
2018-03-14	54		#: 3117 patent”); 9,675,610 (the “’610 patent”); and 10,076,497 (the “’497 patent”) (collectively… (PATENT INFRINGEMENT OF U.S. PATENT NO. 9,675,610) 68. …United States Patent Nos. 9,775,808 (the “’808 patent”); 9,763,886 (the “’886 patent”); 9,763,933 (…the ’610 patent from Grünenthal, with the right to enforce the ’610 patent. The ’610 patent is listed… ’497 patent were allowed by the U.S. Patent and Trademark Office and would issue in a patent. Defendants	External link to document

Litigation Summary and Analysis for Purdue Pharma L.P. v. Intellipharmaceutics International Inc. | 1:18-cv-00404

Last updated: February 4, 2026

---

What is the case about?

Purdue Pharma L.P. filed a patent infringement lawsuit against Intellipharmaceutics International Inc., alleging that the defendant's generic opioid formulations infringed on Purdue's patents related to abuse-deterrent opioid products.

Key Patent and Product Details

• Patent in dispute: U.S. Patent No. 9,817,769, titled "Abuse-Deterrent Formulations of Opioids." The patent claims specific formulations designed to reduce tampering and misuse.
• Defendant’s product: Intellipharmaceutics' generic versions of Purdue's abuse-deterrent formulations, including opioid tablets intended to deter crushing, melting, or dissolving.

Legal Claims

• Patent Infringement: Purdue alleged that Intellipharmaceutics' generic opioids infringed on its patent rights under 35 U.S.C. § 271(a), (b), and (c).
• Patent Validity: Purdue maintained the patents are valid and enforceable, supported by patent prosecution history and technical specifications.
• Infringement Analysis: Purdue contended that the generic products incorporate each element of the patent claims, specifically the abuse-deterrent properties.

Procedural History

• Filing date: The complaint was filed on January 17, 2018 [1].
• Initial motions: Intellipharmaceutics filed a motion to dismiss the patent infringement claims, arguing patent invalidity and non-infringement.
• Summary judgment: The court granted partial summary judgment in favor of Purdue, affirming patent infringement on certain claims, while invalidity arguments were contested.

Key issue points

• Infringement by equivalence: Purdue argued that the generic formulations meet the essential elements of the patent claims.
• Obviousness challenge: Intellipharmaceutics argued that the patent claims were obvious in light of prior art, specifically U.S. Patent No. 8,821,865 and other references.
• Patent prosecution history: Purdue maintained that the patent claims are supported by specific technical features explicitly disclosed during patent prosecution.

Court's decisions and rulings

• Infringement: The court found that Purdue demonstrated a genuine issue of material fact regarding infringement, denying the motion for summary judgment of non-infringement.
• Validity: Purdue’s argument for patent validity remained unchallenged in the rulings, though patent invalidity remains pending in related proceedings.
• Damages and injunctions: The case has yet to reach a damages or injunction phase; the court has scheduled further proceedings on infringement and validity issues.

Legal implications and industry context

• The case exemplifies ongoing patent battles in the opioid space, where companies seek to enforce abuse-deterrent formulation patents.
• The proceedings reflect broader legal strategies used by brand-name pharmaceutical companies to prevent generic competition.
• Patent validity challenges, particularly on obviousness grounds, remain central to patent disputes in this domain.

Current status

• As of the latest filings (2023), the case remains active with scheduled trial proceedings for infringement and validity issues.
• No final judgment or settlement has been publicly reported.

---

Key Takeaways

• Patent litigation around abuse-deterrent opioids continues to be a high-stakes area, balancing patent enforcement against challenges based on obviousness.
• Purdue's patent protections remain enforceable, with ongoing disputes over infringement by generics.
• The case highlights the importance of detailed patent claims and prosecution history in defending patent rights.
• Patent invalidity defenses, particularly regarding prior art and obviousness, are frequently raised in this sector.
• Litigation outcomes influence the availability of abuse-deterrent formulations in generic markets, impacting pricing and access.

---

FAQs

1. What are abuse-deterrent formulations?
They are drug formulations designed to prevent tampering, crushing, dissolving, or melting, to reduce misuse and abuse of opioids.

2. How do patent disputes impact the opioid market?
They can delay generic entry, maintaining high prices for brand-name products while protecting market share.

3. What defenses do generics typically use in patent infringement cases?
Common defenses include arguing patent invalidity based on prior art or obviousness, non-infringement, and unenforceability.

4. How does obviousness challenge patent validity?
It claims that the invention would have been obvious to someone skilled in the field at the time the patent was filed, rendering it invalid under 35 U.S.C. § 103.

5. When might this case affect the availability of generic abuse-deterrent opioids?
A decision in favor of Purdue could delay generic approval; a ruling invalidating the patent could accelerate generic market entry.

---

Sources

[1] Court filings and docket information from PACER (Public Access to Court Electronic Records).